Identification
- Generic Name
- Pumactant
- DrugBank Accession Number
- DB04955
- Background
Pumactant is a synthetic surfactant used for treating respiratory distress syndrome in neonates. It is a unique formulation of the naturally occurring phospholipids Dipalmitoylphosphatidycholine (DPPC) and Phosphatidyl Glycerol (PG).
- Type
- Small Molecule
- Groups
- Investigational
- Synonyms
- ALEC
Pharmacology
- Indication
Investigated for use/treatment in asthma, lung injury, and surgical adhesions.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
Pumactant is known as a lung (pulmonary) surfactant. Surfactants are wetting agents which coat the surface of the air sacs (alveoli) and reduce surface tension in the lungs. This helps to inflate and expand the air sacs during breathing and prevents their collapse. Surfactants are normally produced naturally in the lungs. A failure by the lungs to do this results in a life threatening disorder known as respiratory distress syndrome, where the lungs become stiff, uninflatable and make breathing extremely difficult. This commonly occurs in premature babies, where their under-developed lungs are incapable of producing surfactants. Pumactant is given directly into the lung through a tube (endotracheal administration), to replace the natural surfactant and therefore aids breathing in premature babies.
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- Not Available
- CAS number
- 258856-56-3
References
- General References
- Babu KS, Woodcock DA, Smith SE, Staniforth JN, Holgate ST, Conway JH: Inhaled synthetic surfactant abolishes the early allergen-induced response in asthma. Eur Respir J. 2003 Jun;21(6):1046-9. [Article]
- Ainsworth SB, Beresford MW, Milligan DW, Shaw NJ, Matthews JN, Fenton AC, Ward Platt MP: Pumactant and poractant alfa for treatment of respiratory distress syndrome in neonates born at 25-29 weeks' gestation: a randomised trial. Lancet. 2000 Apr 22;355(9213):1387-92. [Article]
- Young PM, Thompson J, Woodcock D, Aydin M, Price R: The development of a novel high-dose pressurized aerosol dry-powder device (PADD) for the delivery of pumactant for inhalation therapy. J Aerosol Med. 2004 Summer;17(2):123-8. [Article]
- External Links
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
- Not Available
- Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Drug created at October 21, 2007 22:23 / Updated at June 12, 2020 16:52